文献速递血液净化与透析

ROMANOV研究:维持性血透患者对SARS-CoV-2 mRNA疫苗的体液和细胞免疫应答受损

The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis.
PubMed 文献 · Kidney Int · 2021-07-18

ROMANOV研究在106例维持性血透患者(14例有COVID-19史)和30名健康志愿者(4例有COVID-19史)中,于第二剂BNT162b2疫苗后10-14天检测抗RBD IgG及产生干扰素γ的CD4+和CD8+特异性T细胞。病毒未暴露的血透患者中90%(72/80)产生至少一种免疫效应,但应答较健康志愿者更弱且不完整;多因素分析显示血透和免疫抑制治疗与缺乏抗RBD IgG及抗spike CD8+ T细胞显著相关。有COVID-19史的血透患者产生的抗RBD IgG和抗spike CD8+ T细胞水平与健康志愿者相似。

要点

  • 病毒未暴露的血透患者接种两剂mRNA疫苗后免疫应答减弱且不完整。
  • 血透和免疫抑制治疗与缺乏抗RBD IgG及抗spike CD8+ T细胞独立相关。
  • 有COVID-19史的血透患者接种后免疫应答与健康志愿者相似。

核心结论

  • 病毒未暴露的维持性血透患者接种两剂mRNA疫苗后产生减弱的免疫应答。
  • 有COVID-19史的血透患者对疫苗应答良好,提示可能受益于第三剂加强接种。

研究设计与样本

  • ROMANOV研究为观察性研究,纳入106例维持性血透患者(14例有COVID-19史)和30名健康志愿者(4例有COVID-19史)。
  • 于第二剂BNT162b2疫苗后10-14天检测循环抗spike RBD IgG及产生干扰素γ的CD4+和CD8+特异性T细胞。

主要发现

  • 病毒未暴露的血透患者中90%(72/80)在接种后产生至少一种免疫效应。
  • 血透患者的免疫应答较健康志愿者更弱且更不完整。
  • 多因素分析显示血透和免疫抑制治疗与缺乏抗RBD IgG及抗spike CD8+ T细胞显著相关。
  • 有COVID-19史的血透患者产生的抗RBD IgG和抗spike CD8+ T细胞水平与健康志愿者相似。

临床怎么用

  • 对病毒未暴露的维持性血透患者,两剂mRNA疫苗可能不足以提供充分保护。
  • 有COVID-19史的血透患者接种后应答良好,可考虑第三剂加强接种。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients on maintenance hemodialysis (MHD), which are at high risk of infection by SARS-CoV-2 virus and death due to COVID-19, have been prioritized for vaccination. However, because they were excluded from pivotal studies and have weakened immune responses, it is not known whether these patients are protected after the "standard" two doses of mRNA vaccines. To answer this, anti-spike receptor binding domain (RBD) IgG and interferon gamma-producing CD4+ and CD8+ specific-T cells were measured in the circulation 10-14 days after the second injection of BNT162b2 vaccine in 106 patients receiving MHD (14 with history of COVID-19) and compared to 30 healthy volunteers (four with history of COVID-19). After vaccination, most (72/80, 90%) patients receiving MHD naïve for the virus generated at least one type of immune effector, but their response was weaker and less complete than that of healthy volunteers. In multivariate analysis, hemodialysis and immunosuppressive therapy were significantly associated with absence of both anti-RBD IgGs and anti-spike CD8+ T cells. In contrast, previous history of COVID-19 in patients receiving MHD correlated with the generation of both types of immune effectors anti-RBD IgG and anti-spike CD8+ T cells at levels similar to healthy volunteers. Patients receiving MHD naïve for SARS-Cov-2 generate mitigated immune responses after two doses of mRNA vaccine. Thus, the good response to vaccine of patients receiving MHD with a history of COVID-19 suggest that these patients may benefit from a third vaccine injection.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Espi M, Charmetant X, Barba T, et al. The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis. Kidney Int. 2021. PMID: 34284044. doi:10.1016/j.kint.2021.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。